Compounded
Semaglutide
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Back to All Reviews
Investigation Report
MDWatch Tirzepatide Review
MDWatch, mdwatch.io, MD Watch
Also spelled as MDWatch, mdwatch.io, MD Watch — Same brand, same great service!
Our investigation of Compounded Tirzepatide from MDWatch
Reviewed
Meets our quality standards
Reviewed
FDA-approved GLP-1s from a $50 Medicare copay if you qualify, or compounded GLP-1s from $90/month, with no membership fees
100+
Hours Researched
10
Verified Pros
7
Issues Found
8.5
Final Score
These are Med Consumer Watch products, not products from MDWatch, the brand being reviewed on this page.
Med Consumer Watch GLP-1 plans
GLP-1 weight loss.
A brand on your side.
Med Consumer Watch exists to help consumers make informed choices. Our brand brings that mission to GLP-1 care: clear plan prices, clinician review and support included, so you can compare your options and get started with confidence.
Why choose Med Consumer Watch?
Know your full price
Medication, clinician review and shipping are included. See your total before you buy.
Same price at every included dose
Your plan price stays the same across its included prescribed doses. Choose 1, 3, 6 or 12 months.
Support beyond your prescription
Ongoing doctor messaging, health coaching and patient community access are included with your plan.
Choose your medication and the plan length that works for you.
Buy semaglutide
Compounded
Tirzepatide
Any prescribed dose up to 15 mg/week
Prescription & clinician review included
Shipping included
$1,548 due today
Treatment requires a prescription and clinician approval. If treatment is declined, your payment is refunded. Compounded medications are not FDA-approved.
Investigation Overview
MDWatch does something almost no operator in this comparison does: it offers both the approved route and the compounded route, prices them side by side, and lets the patient choose with the numbers in front of them. Our research (September 1, 2026) found a Medicare-oriented practice built around monitoring rather than dispensing.
Two Routes, Both Priced
"Eligible patients may receive FDA-approved GLP-1 medications through the Medicare GLP-1 Bridge Program or affordable compounded GLP-1 medications, with ongoing provider support."
"From $50/mo — FDA-approved GLP-1s with Medicare • Compounded from $90 • No fees"Presenting both paths honestly is more useful than picking one. A senior who qualifies for the Bridge program gets an approved product for a $50 copay, which is the better clinical outcome; one who does not can see the compounded alternative and its price without having to go elsewhere. Most operators sell only compounded and never mention that an approved route might be cheaper. MDWatch states there are no membership or subscription fees on either path.
The Compounded Option Still Carries Its Caveats
Where MDWatch dispenses compounded medication it describes it as "clinically appropriate, compounded GLP-1 medication dispensed by licensed pharmacies pursuant to a prescription," and notes results have not been independently verified. The standard position applies: compounded drugs are not FDA-approved, are not reviewed for safety, effectiveness or manufacturing quality, and are not therapeutically equivalent to the branded products. Following resolution of the tirzepatide shortage in October 2024 and semaglutide in early 2025, lawful 503A compounding requires a documented patient-specific clinical rationale. If you qualify for the $50 Bridge route, take it over the $90 compounded route. The $40 difference buys FDA review.The Program Is Monitoring, Not Just a Prescription
"Plus your care team, monitoring & cellular smart scale — covered by Medicare. The whole program, not just a prescription."Included care is described as personalised treatment, ongoing support, lab review and a connected scale. Alongside weight management, MDWatch runs a diabetes program pairing continuous glucose monitoring — Dexcom G7 or FreeStyle Libre — with a clinician who reads the data:
"A glucose monitor your care team reads for you — most patients pay $0 with Medicare."For an older population on GLP-1s, where lab review and glycaemic monitoring genuinely matter, a monitoring-led model is the clinically appropriate one. A cellular scale that transmits without the patient operating an app is a sensible design choice for this demographic.
The Clinicians Are Named and Checkable
"Every provider is a licensed U.S. clinician. Doctors and nurse practitioners you can look up by name — they're all introduced below."The team is described with credentials and tenure: board-certified with 20 years' experience; dual board-certified with 25+ years and clinical faculty appointment; board-certified FNP-C with 30+ years; board-certified in telehealth with 20 years. Inviting patients to look clinicians up by name is a verifiable claim rather than an assertion.
Low-Friction Entry, Honestly Framed
"Free 15-minute consult, no obligation. No Medicare card needed to start."The site includes a section headed "the honest part about Medicare," explaining in plain language what Medicare does and does not cover — provider visits, remote monitoring and lab work, for which most patients pay little or nothing. Framing coverage limits explicitly, rather than implying everything is free, is the right posture for an audience that is frequently misled on exactly this point.
What Is Not Published
No compounding pharmacy is named and no 503A/503B status is given for the compounded route. No BMI or clinical eligibility criteria for the compounded path — the Bridge programme has its own Medicare-defined criteria, but MDWatch's own standard is not stated. No titration protocol, no explicit monitoring cadence, no founding year, and no dose-tier pricing showing what the compounded option costs at a maintenance dose.Our Investigation Summary
Our research (September 1, 2026) found MDWatch operating a Medicare-focused telehealth practice for seniors that, unusually, offers and prices both routes to a GLP-1: FDA-approved medication through the Medicare GLP-1 Bridge Program from a $50 monthly copay for those who qualify, or compounded GLP-1 medication from $90 per month for those who do not, with no membership or subscription fees on either. Presenting both openly is more useful than the category norm of selling only compounded product without mentioning that an approved route may be available and cheaper. The program is built around monitoring rather than dispensing alone: included care is described as personalised treatment, ongoing provider support, lab review and a cellular connected smart scale, with the company framing it as "the whole program, not just a prescription." A parallel diabetes program pairs continuous glucose monitoring via Dexcom G7 or FreeStyle Libre with clinicians who read the data, at $0 with Medicare for most patients. For an older population on GLP-1s — where lab review, glycaemic monitoring and lean-mass considerations matter — a monitoring-led design is clinically appropriate, and a cellular scale requiring no app interaction is a sensible choice for the demographic. Clinical staff are named with credentials and tenure, described as board-certified with 20 years, dual board-certified with 25+ years and a clinical faculty appointment, board-certified FNP-C with 30+ years, and board-certified in telehealth with 20 years, with the company inviting patients to look providers up by name. Entry is low friction and honestly framed: a free 15-minute consult with no obligation and no Medicare card needed to start, plus a section headed "the honest part about Medicare" setting out in plain language what Medicare does and does not cover. Where MDWatch dispenses compounded medication the usual caveats apply — not FDA-approved, not reviewed for safety, effectiveness or manufacturing quality, not therapeutically equivalent to branded products, and subject to the post-shortage requirement for a documented patient-specific rationale — and a patient who qualifies for the $50 approved route should prefer it to the $90 compounded one. Not published: any named compounding pharmacy or its 503A/503B status, MDWatch's own BMI or clinical eligibility criteria for the compounded path, titration protocols, an explicit monitoring cadence, dose-tier pricing for the compounded option at maintenance doses, or founding year.
How MDWatch Works
1
Book a free 15-minute consult — no obligation, no Medicare card needed to start
2
A licensed US clinician reviews your history and coverage position
3
If you qualify, FDA-approved GLP-1s come via the Medicare GLP-1 Bridge at a $50 copay
4
If you do not qualify, compounded GLP-1 medication starts from $90/month
5
Prefer the approved route where you qualify — the $40 difference buys FDA review
6
Care includes lab review, ongoing support and a cellular connected smart scale
7
Provider visits, remote monitoring and lab work are largely covered by Medicare
8
A parallel diabetes program adds CGM read by your care team, $0 with Medicare for most
What We Found
What's Good
- Offers and prices both routes — FDA-approved via Medicare from $50, compounded from $90
- Tells seniors an approved route exists rather than selling only compounded product
- No membership or subscription fees on either path
- Clinicians named with credentials and tenure, and patients invited to look them up
- Monitoring-led: lab review, ongoing support and a cellular connected smart scale included
- Diabetes program adds CGM (Dexcom G7 / FreeStyle Libre) read by the care team
- Free 15-minute consult, no obligation, no Medicare card needed to start
- Plain-English section explaining what Medicare does and does not cover
- Provider visits, remote monitoring and lab work largely covered by Medicare
- Cellular scale requires no app interaction — appropriate for the demographic
Watch Out For
- No compounding pharmacy named and no 503A/503B status disclosed
- No dose-tier pricing for the compounded route at maintenance doses
- No BMI or clinical eligibility criteria published for the compounded path
- The $50 route depends on Medicare qualification you may not meet
- No titration protocol or explicit monitoring cadence published
- Built for seniors on Medicare — not a general-market service
- No founding year, support hours or refund policy published
Pricing Breakdown
Starting Price
FDA-approved GLP-1s from a $50 monthly copay via the Medicare GLP-1 Bridge Program if you qualify; compounded GLP-1s from $90/month if you do not
Medication Cost
The $50 is a Medicare copay for an approved product, not a price MDWatch sets. The compounded route starts at $90/month; no dose-tier structure is published for it
Subscription Fees
None. MDWatch states there are no membership or subscription fees on either route
Hidden Fees
None identified. Provider visits, remote monitoring and lab work are described as largely covered by Medicare, with most patients paying little or nothing. The initial 15-minute consult is free with no obligation
Safety & Medical Oversight
MDWatch's clinical structure is well suited to the population it serves. It names its clinicians with credentials and tenure — board-certified with 20 years' experience, dual board-certified with 25+ years and a clinical faculty appointment, a board-certified FNP-C with 30+ years, and a clinician board-certified in telehealth with 20 years — and explicitly invites patients to look providers up by name, which makes the claim verifiable rather than assertive. Care is described as monitoring-led rather than prescription-only: lab review, ongoing provider support and a cellular connected smart scale are included, and a parallel diabetes program pairs continuous glucose monitoring through Dexcom G7 or FreeStyle Libre with clinicians who read the data on the patient's behalf. For older adults on GLP-1 therapy, where laboratory review and glycaemic monitoring carry real clinical weight and where lean-mass loss is a genuine concern, that emphasis is appropriate. Most significantly, MDWatch offers an FDA-approved route: eligible Medicare patients may obtain approved GLP-1 medications through the Medicare GLP-1 Bridge Program at a $50 copay, which avoids the compounded-preparation risks entirely. Patients who qualify should take that route in preference to the compounded option at $90. Where compounded medication is dispensed, MDWatch describes it as clinically appropriate compounded GLP-1 medication dispensed by licensed pharmacies pursuant to a prescription and notes that results have not been independently verified, but the standard caveats apply: compounded preparations are not FDA-approved, are not reviewed for safety, effectiveness or manufacturing quality, are not therapeutically equivalent to branded products, and following resolution of the tirzepatide and semaglutide shortages lawful 503A compounding requires a documented patient-specific clinical rationale. What we could not establish: the name or 503A/503B status of the compounding pharmacy used, MDWatch's own BMI or clinical eligibility criteria for the compounded path, the titration protocol applied, and the explicit cadence of monitoring contacts. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumours and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Customer Support
MDWatch is built around continuing contact rather than fulfilment, which is the correct emphasis for its Medicare population. A free 15-minute consult with no obligation and no requirement to produce a Medicare card is offered as the entry point, and the company invites coverage and pricing questions directly, stating that its licensed US care team will answer them and offering to "talk to a real person." Ongoing care includes provider support, lab review, remote monitoring and a cellular connected smart scale that transmits readings without the patient operating an app — a design choice that removes a real barrier for older users. The diabetes program extends this with continuous glucose monitoring that the care team reads on the patient's behalf rather than leaving interpretation to the patient. The service is described as HIPAA-secure, using licensed US pharmacies and board-certified clinicians, and clinicians are introduced by name with credentials so patients can verify them independently. A dedicated section explains Medicare coverage in plain English, including what is and is not covered. What we found no published information on: specific support hours, a response-time commitment, the explicit cadence of follow-up contacts, or a cancellation and refund policy.
Key Features
FDA-Approved from $50/mo
Compounded from $90/mo
No Membership Fees
Named Board-Certified Clinicians
Cellular Smart Scale Included
Lab Review Included
CGM via Dexcom / FreeStyle Libre
Free 15-Minute Consult
Best For
Seniors on Medicare who want a clinician-monitored program rather than a prescription pipeline, and who want to see the approved and compounded routes priced side by side before choosing
Customer Reviews & Complaints
We assessed MDWatch against its published material as of September 1, 2026.
What we verified directly: FDA-approved GLP-1s offered from a $50 monthly copay through the Medicare GLP-1 Bridge Program and compounded GLP-1s from $90/month, with no membership or subscription fees; a free 15-minute consult requiring no Medicare card; named clinicians with stated board certifications and tenure; inclusion of lab review, remote monitoring and a cellular connected smart scale; a diabetes program with Dexcom G7 and FreeStyle Libre CGM at $0 with Medicare for most patients; and a plain-English explanation of Medicare coverage limits.
Offering both routes is the finding that matters most. The commercial incentive in this category runs entirely toward compounded product, because margins are higher and no payer is involved. A practice that tells a Medicare patient they may be able to get an FDA-approved drug for $50 — $40 less than its own compounded option — is acting against that incentive.
Naming clinicians and inviting verification is the second signal. "Doctors and nurse practitioners you can look up by name" is a checkable claim, and stated tenure of 20 to 30 years is unusual in a category staffed largely by anonymous provider networks.
The monitoring inclusions are substantive, not decorative. Lab review and a connected scale that transmits without app interaction are the things that make GLP-1 therapy safer in an older population, and they are bundled rather than upsold.
The gap is on the compounded side. No pharmacy is named, no 503A/503B status given, and no dose-tier pricing published — so a patient taking the $90 route cannot see who compounds their medication or what it will cost at a maintenance dose.
What we could not establish: the compounding pharmacy and its pathway, MDWatch's own eligibility criteria, titration protocols, monitoring cadence, refund terms, founding year, or independent third-party review aggregates.
Is MDWatch Legit?
"Is MDWatch legit?" Our assessment as of September 1, 2026.
Official Verification: MDWatch presents as a licensed US medical practice serving Medicare patients, describing itself as HIPAA-secure, using licensed US pharmacies and board-certified clinicians, and introducing its doctors and nurse practitioners by name with credentials so patients can verify them. It works within Medicare, including the GLP-1 Bridge Program and Medicare-covered remote monitoring and lab work. We found no evidence of wrongdoing.
Working inside Medicare is itself an accountability structure. Billing a payer for provider visits, remote monitoring and lab work brings credentialing and audit exposure that a cash-only compounded telehealth site does not face.
The strongest ethical signal is what MDWatch tells you about the cheaper option. It could sell only compounded GLP-1s at $90 and never mention the Bridge programme. Instead it leads with the $50 approved route. Compare Bold, which takes the same approved-only position for the same population.
"The honest part about Medicare" is worth reading. Setting out plainly what Medicare covers and what it does not, for an audience routinely misled on exactly that, is the opposite of how coverage is usually marketed to seniors.
Where to press. If you end up on the compounded route, ask which pharmacy compounds it, whether it operates under 503A or 503B, and what the price becomes at a maintenance dose. Ask too whether you might qualify for the Bridge programme through another route such as type 2 diabetes.
Red Flags Check:
- ✓ Offers FDA-approved medication via Medicare, not compounded only
- ✓ Prices both routes openly and leads with the cheaper approved one
- ✓ No membership or subscription fees
- ✓ Clinicians named with credentials; patients invited to verify them
- ✓ Lab review, remote monitoring and connected scale included
- ✓ CGM read by the care team rather than left to the patient
- ✓ Free consult with no obligation and no Medicare card required
- ✓ Plain-English disclosure of Medicare coverage limits
- ⚠ Compounding pharmacy unnamed; 503A/503B status undisclosed
- ⚠ No dose-tier pricing for the compounded route
- ⚠ No BMI or eligibility criteria published for the compounded path
- ⚠ No titration protocol, monitoring cadence or refund policy published
The Bottom Line: A well-constructed program for Medicare seniors that treats GLP-1 therapy as something to monitor rather than merely dispense, and that points patients toward the FDA-approved route it earns less from. If you qualify for the $50 Bridge copay, take it over the $90 compounded option. If you do not, ask which pharmacy compounds your medication before starting. As always, consult your personal physician before starting any new medication program.
Our Verdict: Reviewed
MDWatch has a 8.5/10 site score. This provider has demonstrated excellent quality, transparent pricing, and reliable customer support. We recommend them for anyone considering GLP-1 treatment.
Visit MDWatchMDWatch
Reviewed
8.5/10
FDA-approved GLP-1s from a $50 Medicare copay if you qualify, or compounded GLP-1s from $90/month, with no membership fees
Prescription treatment requires clinician review
Investigation Summary
Overall Rank#209 of 226
Rating8.5/10
StatusReviewed
PricingFDA-approved GLP-1s from a $50 Medicare copay if you qualify, or compounded GLP-1s from $90/month, with no membership fees
Share Your Experience
Help others by sharing your experience with MDWatch
Want to compare options?
View All 226 ProvidersUser Reviews
Rating Summary
No ratings yet
Rate your experience
Click a star to rate and add a review
Questions & Discussions
226 Providers Reviewed
Explore Other Reviews
Compare with other GLP-1 weight loss providers we've investigated
Our Top Picks
#1 RecommendedExcellent
#2 RecommendedExcellent
#3 RecommendedExcellent
More Provider Reviews
CoreAge Rx
9.9
SuperHealthy Rx
9.7
Likeness Rx
9.5
Mochi Health
8.8
Remedy Meds
8.3
Reviewed
Ready to Get Started with MDWatch?
Based on our investigation, MDWatch is a trusted choice for GLP-1 treatment. Join thousands who have started their weight loss journey.
Enter to Win a $1,788 CoreAge Rx Gift Card
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.